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Abstract
Patients with episodic sinus tachycardia and associated orthostatic intolerance present  
a diagnostic and management dilemma to the clinician. We define this group of disorders to 
include sinus node reentrant tachycardia (SNRT), inappropriate sinus tachycardia (IAST), 
and postural orthostatic tachycardia syndrome (POTS). After a brief review of the current 
understanding of the pathophysiology and epidemiology of this group of disorders, we focus on  
the diagnosis and management of IAST and POTS. Our approach attempts to recognize the 
considerable overlap in pathophysiology and clinical presentation between these two heteroge-
neous conditions. Thus, we focus on a mechanism-based workup and therapeutic approach. 
Sinus tachycardia related to identifiable causes should first be ruled out in these patients. 
Next, a basic cardiovascular and autonomic workup is suggested to exclude structural heart 
disease, identify a putative diagnosis, and guide therapy. We review both nonpharmacologic 
and pharmacologic therapy, with a focus on recent advances. Larger randomized control trials 
and further mechanistic studies will help refine management in the future. (Cardiol J 2014; 
21, 6: 665–673)
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Introduction
Patients with episodic sinus tachycardia (ST) 
and associated orthostatic intolerance (OI) present 
a diagnostic and management dilemma to the clini-
cian. These patients often experience severe symp-
toms exacerbated in the upright position. Although 
ST in the absence of any significant heart disease is 
usually associated with a benign prognosis, increas-
ed heart rate (HR) over time may be an indepen-
dent risk factor for all-cause mortality in selected 
populations [1]. The dictum for approaching patients 
with ST is to treat the underlying cause, because so 
often ST represents a normal heart’s response to 
physiologic stress. Despite multiple investigations, 
for many patients this “underlying cause” cannot be 
determined. Patients frequently have a combination 
of paroxysmal or nonparoxysmal ST, palpitations, 
atypical chest discomfort, exercise intolerance, OI, 
presyncope, and syncope. The differential diagnosis 
in patients with symptomatic ST includes sinus 
node reentrant tachycardia (SNRT), inappropriate 
ST (IAST), and postural orthostatic tachycardia 
syndrome (POTS). While our understanding of the 
underlying pathophysiologic mechanisms remains 
limited, recent research has provided new insights 
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Definitions and clinical presentation
Sinus tachycardia is defined as an atrial rate 
more than 100 bpm with P waves originating from 
the sinoatrial node at the superior aspect of the 
crista terminalis, resulting in a positive wave in 
leads I, aVL, II, III, and aVF. Four heterogenous 
conditions have this finding: normal ST, SNRT, 
IAST, and POTS. Normal ST is the most common 
ST and is the appropriate increase in sinus node 
rate in response to physiologic stimuli. We will not 
review this well-described entity [2, 3].
Sinus node reentrant tachycardia is a primary 
arrhythmia that involves a reentry circuit in the 
region of the sinoatrial node, likely mediated by 
the anisotropic conduction [4]. It is characterized 
by paroxysmal episodes of tachycardia, generally 
100–150 bpm [5, 6]. In contrast, IAST is not par-
oxysmal, with an average daily HR of 95 bpm or 
higher. It is thought to represent increased automa-
ticity of the sinus node that is inappropriate for the 
degree of physiologic demand [3, 7]. The intrinsic 
HR changes with age; thus the specific threshold 
used to define IAST may be better conceived of as 
an age-dependent variable. However, consensus on 
an age-adjusted definition has not been reached. 
Although IAST is not paroxysmal, the symptoms 
may be intermittent and often include atypical 
chest discomfort, exercise intolerance, and OI. 
POTS is characterized by marked tachycardia in 
the upright posture accompanied by labile blood 
pressure and severe OI. Symptoms are thought to 
be related to relative cerebral hypoperfusion [3, 8]. 
POTS has been defined as an increase in HR of 
30 bpm or more within 10 min of adopting upright 
posture in the absence of orthostatic hypotension 
[9, 10]. The clinical definitions of IAST and POTS 
are compared in Table 1.
Orthostatic intolerance is the occurrence of pal-
pitations, fatigue, nausea, malaise, presyncope, or 
syncope upon assuming an upright posture [11–13], 
secondary to relative cerebral hypoperfusion, 
which distinguishes it from hyperventilation [14, 
15] and psychogenic pseudosyncope [16]. While ST 
is not always associated with OI, the two findings 
intersect to varying degrees among patients with 
POTS, IAST, and SNRT. The differential diagnosis 
of these conditions and their approximate associa-
tion with OI are depicted in Figure 1.
Epidemiology and pathophysiology
In general, SNRT, IAST, and POTS are uncom-
mon and the epidemiological data is incomplete. 
SNRT is distinguished from the other two conditions 
in that it is a primary arrhythmia. It is reported to 
occur more commonly in patients with structural 
heart disease, and like other reentry tachycardias, 
it can be induced during an electrophysiologic study 
by programmed stimulation and localized to the area 
of the sinus node in the region of superior crista 
terminalis. Pacing maneuvers such as entrainment 
can confirm a reentry mechanism [17].
IAST occurs more frequently in young women 
in their fourth decade of life. Although the precise 
causes are ill-defined, the following plausible 
mechanisms have been proposed: increased rest-
ing sympathetic tone, decreased parasympathetic 
response, impaired baroreflex sensitivity, elevated 
intrinsic sinus node rate, enhanced automaticity of 
the sinus node, or positive chronotropic effects of 
anti–beta adrenergic receptor antibodies [18–20]. 
Given the early age of onset, there may be a devel-
opmental component to IAST, although no direct 
evidence exists at this time.
POTS also occurs more frequently in young 
women (female:male ratio — 4.5:1), and most cases 
occur between the ages of 15 and 25 years. Up 
to 50% of cases have an antecedent viral illness, 
and 25% have a family history of similar complaints 
[9, 10]. The primary mechanism is venous pooling 
and central hypovolemia during upright posture, 
resulting in secondary sympathetic excitation that 
perpetuates the tachycardic response [21, 22]. 
Table 1. Clinical features of inappropriate sinus tachycardia (IAST) and postural orthostatic tachycardia 
syndrome (POTS).
IAST POTS
Heart rate “Inappropriate” for physiologic need  
> 90–100 bpm at rest or  
with minimal exertion
Persistent increase > 30 bpm or absolute rate 
> 120 bpm within 10 min when moving from 
supine to upright position
Mean > 95 bpm on Holter Absence of orthostatic hypotension
Symptoms Frequently multi-system Frequently multi-system, though greater  
associated with orthostatic intolerance
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Autoimmunity may exert an effect; elevated alpha-1 
receptor partial antagonist and beta-1 receptor, beta-2 
receptor agonist autoantibodies were identified 
in the serum of POTS patients [23]. Anxiety and 
depression are not uncommon in POTS and IAST 
patients, but the psychiatric contribution to symp-
toms is unclear. One recent study suggests that 
palpitations are an effect of sympathetic stimulation 
and independent of the actual HR. Studies also 
demonstrated that POTS patients did not differ in 
somatosensory amplification compared to controls, 
suggesting that symptoms are not psychogenic [24]. 
The apparent decrease in symptoms upon admini-
stration of placebo may be because of physiological 
changes over time, rather than a psychologically 
conditioned response [25]. The question remains 
whether POTS and IAST are two distinct syndro-
mes with significant overlapping clinical features or 
whether there are “shared” mechanisms. A recent 
study comparing POTS with IAST demonstrated 
that the intrinsic HR did not differ between the 
two conditions and healthy controls after autonomic 
blockade with propranolol and atropine. However, 
patients with IAST showed a larger HR reduction 
after sympathetic blockade with propranolol when 
compared with POTS patients. This study elegantly 
demonstrated that the tachycardia of IAST is mainly 
mediated by enhanced sympathetic tone; however, 
a limited autonomic dysregulation in POTS during 
orthostatic stress cannot be excluded [22].
Evaluation and diagnosis
Patients with SNRT, IAST, or POTS often pre-
sent with similar symptoms, including palpitations, 
lightheadedness, presyncope, and sometimes synco-
pe with various degrees of OI. The overall approach 
to these patients has three facets: (1) to exclude 
underlying structural heart disease and primary 
metabolic causes; (2) to determine a diagnosis; and 
(3) to define a mechanism for the patient’s symp-
toms in order to guide effective therapy [26].
A thorough history is taken to characterize the 
patient’s symptoms. Special consideration should 
be given to the symptom onset, chronicity, and 
correlation with posture. Cardiovascular risk factors 
should be assessed. Symptoms that would indicate 
a secondary cause of normal ST should be elicited 
by a thorough review of systems. Both patients with 
POTS and those with IAST often have multi-system 
complaints with autonomic features (temperature 
sensitivity, genitourinary or gastrointestinal symp-
toms, and tremor) [9], and autonomic features do not 
reliably distinguish between diagnoses [26].
Initial studies should routinely include twelve-
-lead electrocardiography (ECG) and 24-h Holter 
monitoring to exclude other causes of supraventric-
ular tachycardia and assess the diurnal variation in 
HR. The P wave morphology should be carefully 
examined and compared to P waves on prior ECGs. 
An echocardiogram is recommended to rule out 
Figure 1. Differential diagnosis of sinus tachycardia (ST) with orthostatic intolerance (OI); general approach and 
differential diagnosis of patients with ST who present with palpitations, autonomic symptoms, and varying levels of OI. 
The variable association of sinus node reentrant tachycardia (SNRT), inappropriate sinus tachycardia (IAST), and 
postural orthostatic tachycardia syndrome (POTS) to OI is depicted.
www.cardiologyjournal.org 667
Aalap D. Narichania et al., Managing the patient with episodic sinus tachycardia and orthostatic intolerance
structural heart disease [8, 26]. Tachycardia-
-induced cardiomyopathy is rare in patients with 
IAST or POTS; thus, left ventricular dysfunction 
should elicit consideration of alternative diagno-
ses. For paroxysmal episodes that have not been 
documented electrocardiographically, a cardiac 
event recorder or implantable loop recorder can be 
helpful to document a spontaneous clinical event. 
While there are no absolute ECG diagnostic criteria 
for these conditions, SNRT is likely when short 
episodes of paroxysmal ST are captured on a car-
diac monitor. IAST is diagnosed in a symptomatic 
patient when persistent ST is demonstrated re-
peatedly on ECG and extended cardiac monitoring. 
If incidentally found asymptomatic HR changes are 
observed that meet IAST criteria, 1 year follow-up 
is reasonable to reassess for normal ST and exclude 
the very rare development of tachycardia-induced 
cardiomyopathy. POTS is diagnosed by document-
ing a HR increment of 30 bpm or more within 
10 min of standing or head-up tilt in the absence 
of orthostatic hypotension; orthostatic symptoms 
must be present.
Laboratory studies are performed to exclude 
anemia, infection, and renal and endocrine abnor-
malities. Plasma norepinephrine, urinary metan-
ephrines, and 24-h urine assays for sodium and 
cortisol are useful in selected patients to rule out 
Cushing’s disease, pheochromocytoma, and neuro-
endocrine tumors. Medication and recreational 
drug use should be reviewed for anticholinergics, 
catecholamines, exogenous thyroid hormone, 
alcohol, caffeine, cocaine, and tobacco.
SNRT is suspected if the patient has brief 
paroxysms of ST that are variably related to activ-
ity. Confirmation of the mechanism requires an 
electrophysiologic study. Induction of SNRT during 
programmed stimulation, demonstration of entrain-
ment, and localization of the tachycardia origin in 
the region of the sinus node confirms the diagnosis. 
Further autonomic testing is not required for this 
condition.
If POTS or IAST with overlap features such as 
OI or other autonomic features are suspected, auto-
nomic testing can be helpful. Not only does such 
testing assist in diagnosis, but it can also help iden-
tify putative mechanisms that underlie the patient’s 
symptoms, thereby directing therapy [27, 28]. The 
most useful form of evaluation in these patients is 
head-up tilt table testing. The normal response to 
head-up tilt table testing is vagal withdrawal and 
sympathetic activation, leading to a physiologic 
increase in blood pressure and HR to preserve 
cerebral perfusion. Patients with POTS features 
may demonstrate a hyperadrenergic response 
during tilt with a sustained increase in HR and 
a narrowed pulse pressure, as seen in Figure 2 [27]. 
Other methods of autonomic testing may be helpful 
in determining whether there is postganglionic 
sudomotor failure or cardiovagal dysfunction. 
Sudomotor function is assessed with the quantita-
tive sudomotor axon reflex test (QSART), which 
quantifies sweating upon acetylcholine challenge. 
Patients with POTS features may have variable 
sudomotor dysfunction. Cardiovagal function is 
assessed with HR variability. An abnormality in 
HR variability with deep breathing suggests para-
sympathetic dysfunction. Finally, the Valsalva ma-
neuver also can be used to assess abnormalities in 
both adrenergic and cardiovagal function. Although 
the availability of autonomic testing is often limited 
to highly specialized centers, patients with severe 
and refractory symptoms should be referred for this 
testing. The role of autonomic testing in patients 
with IAST has not been clearly defined.
Therapy
SNRT can be terminated acutely by vagal 
maneuvers because the sinus node is sensitive to 
vagal inputs. Intravenous adenosine, beta-blockers, 
verapamil, or diltiazem can also be effective acu-
tely. Recurrent or symptomatic SNRT can be 
successfully treated with radiofrequency ablation, 
which permanently interrupts the reentry circuit. 
Once the diagnosis is confirmed during an electro-
physiology study, low power (10–30 Watt) is used 
during ablation to minimize damage to the sinus 
node itself. Multiple studies have demonstrated the 
safety and efficacy of ablation [17, 29, 30].
Management of IAST and POTS is considered 
together since as there is often significant overlap 
in the clinical presentation, putative mechanism, 
and treatment [26]. Management of IAST and 
POTS can be difficult, often requiring a multi-modal 
approach due to the heterogeneity of these syndro-
mes. Traditionally, treatment of POTS and IAST 
has focused on intravascular volume expansion 
[9] and suppression of the HR [7], respectively. 
However, a mechanistic strategy may be helpful 
in these patients, especially for those who have 
features of both disorders. Our approach is to define 
the physiologic basis of a patient’s symptoms with 
the cardiovascular and autonomic testing discus-
sed, in order to form a basis for targeted therapy 
(Fig. 3). Autonomic testing combined with head-up 
tilt table testing most frequently identifies one of 
four particular responses: (1) hypovolemia and 
668 www.cardiologyjournal.org
Cardiology Journal 2014, Vol. 21, No. 6
venous pooling with variable transient orthostatic 
hypotension, (2) adrenergic failure, (3) cardiovagal 
dysfunction, or (4) a hyperadrenergic state.
Most patients with POTS or IAST will benefit 
from intravascular fluid expansion and elevation of 
the head of the bed to at least 15 degrees. Initially, 
Figure 2. Tilt response in postural orthostatic tachycardia syndrome (POTS). Heart rate and blood pressure response 
to tilt in a typical POTS patient. Tilt occurs at approximately 275 s. Please see text for discussion; HR — heart rate; 
SBP — systolic blood pressure; DBP — diastolic blood pressure.
Figure 3. Overview of the approach to therapy in inappropriate sinus tachycardia (IAST) and postural orthostatic 
tachycardia syndrome (POTS).
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plasma expansion can be achieved with generous 
salt supplementation (> 10 g daily) and fluid intake 
(> 2 L daily). If evidence of hypovolemia persists, 
fludrocortisone can be initiated at 0.1 mg/day and 
titrated up to 1 mg/day in young patients. There is 
also evidence from a recent randomized crossover 
study that desmopressin (0.2 mg, once) decreases 
tachycardia and ameliorates symptoms in POTS [31].
Patients with venous pooling benefit from 
compression stockings, which are recommended if 
discomfort does not preclude their use. Isometric 
exercises in the form of physical counterpressure 
maneuvers have been found to successfully abort 
syncope in patients with vasovagal syncope by 
acutely increasing venous return and peripheral 
resistance [32]. Although physical counterpressure 
maneuvers have not been systematically evaluated 
in patients with POTS, these interventions are 
associated with minimal risk and are potential-
ly useful in patients who are prone to syncope. 
Chronically enhancing venous return through re-
sistance training has shown some benefit as well. 
Inspiratory resistance devices, which are thought 
to increase negative intrathoracic pressure, have 
also demonstrated positive results in patients with 
orthostatic hypotension [33], but effectiveness 
in patients with POTS or IAST and OI has yet to 
be demonstrated. If conservative measures are 
ineffective, then midodrine may reduce OI by 
increasing venous return via alpha agonist activity. 
However, midodrine can cause supine hyperten-
sion because of its vasopressor effect. Midodrine 
is also useful for patients experiencing peripheral 
adrenergic failure or dysfunction, revealed by 
a loss or attenuated late phase II response during 
the Valsalva maneuver [28].
In patients with cardiovagal dysfunction, as 
evidenced by both an abnormal HR response to 
deep breathing and an abnormal Valsalva ratio, 
acetylcholinesterase inhibition with pyridostig-
mine may have symptomatic benefit both acutely 
and over time [34, 35]. Pyridostigmine has been 
studied in patients diagnosed with POTS but may 
be helpful in IAST if there is mechanistic evidence 
of cardiovagal dysfunction. The most common side 
effect is gastrointestinal disturbance.
Autonomic testing may reveal an exaggerated 
phase IV of Valsalva, indicating a hyperadrenergic 
state. Although this mechanism is most often 
associated with IAST, hyperadrenergic POTS has 
been described. Recent studies have demonstrated 
increased exercise capacity in POTS with use of 
low-dose propranolol [36, 37]. POTS and IAST pa-
tients may be highly sensitive to beta-blockers and 
develop many side effects; thus these agents should 
be initiated at a low dose and titrated slowly. Iva-
bradine is a specific If current blocker that directly 
slows the HR by inhibiting sinus node automaticity. 
It has been approved in Europe for the treatment 
of patients with coronary disease and ischemic 
symptoms. Ivabradine has been stud ied in patients 
with IAST with POTS features, and it relieved 
symptoms in approximately 60% of subjects in 
a retrospective study of 20 patients. In a crossover 
study of 21 patients with IAST and randomization 
to ivabradine or placebo, the ivabradine cohort 
experienced significantly decreased HR and conco-
mitantly improved symptoms, with 47% reporting 
complete symptom elimination [38]. Similarly, in 
a more recent study of 20 patients with IAST, 70% 
achieved symptomatic relief when randomized to 
ivabradine, while only 45% achieved symptomatic 
relief from metoprolol succinate [39]. Thus ivabradi-
ne has shown particular benefit in IAST; however, 
larger trials with longer follow-up are needed.
Catheter ablation in patients with POTS or 
IAST has produced disappointing results. Although 
the ablation can be effective in slowing the sinus 
rate, symptoms often persist and may even inten-
sify. Additional risks include a new requirement for 
a pacemaker, phrenic nerve paralysis, and superior 
vena cava stenosis. We do not recommend catheter 
ablation for sinus node modification in POTS [40]. 
Trials of catheter ablation in IAST have demon-
strated a high rate of symptom recurrence, even 
with resolution of tachycardia. Lee et al. [41] repor-
ted 12 patients undergoing initially successful sinus 
node modification, with 2 developing recurrent 
IAST and 4 others developing recurrent symptoms. 
Man et al. [42] reported a series of 29 patients who 
underwent endocardial radiofrequency ablation 
after mapping sites of earliest activation during 
isoproterenol infusion; 34% of patients had recur-
rent symptoms. Marrouche et al. [43] reported 
a 44% recurrence of symptoms after 39 patients 
with IAST underwent sinus node modification gu-
ided by nonfluoroscopic electroanatomic mapping, 
even though implanted loop recorder monitoring 
failed to identify recurrent IAST in symptomatic 
patients. Evidence from these observational cohort 
studies does not support routine consideration of 
sinus node modification in patients with IAST.
Future
While management of SNRT is straightforward, 
management of IAST and POTS continues to be 
largely inadequate. The primary issue with treating 
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patients with orthostatic intolerance and ST is finding 
a single target to treat. The traditional targets have 
been total body fluid (salt, hydration, fludrocortisone), 
sinus node modulation (beta-blockers, ivabradine), 
and blood pressure (midodrine, desmopressin). 
The problem is that each of these treatments is 
a continuous maintenance therapy for paroxysmal 
symptoms. For pharmacologic interventions, this 
results in a situation where patients have a higher 
burden of side effects than relief of symptoms.
Conceptually, there are three models of disease 
treatment for these conditions. The first (Fig. 4) 
is a model of the current state of therapy, where 
chronic maintenance medications or a procedure 
with permanent consequences is used to try to shift 
the patient’s current physiological parameters so 
that the patient crosses the symptom threshold 
fewer times. If the blood pressure is targeted (such 
as treatment with midodrine), supine hypertension 
may occur. If the HR is targeted (such as with 
treatment with a beta-blocker), the blood pressure 
may worsen. Time has proved that this paradigm 
is inadequate for many patients.
In vasovagal syncope, symptom-initiated 
interventions have been shown to be effective in 
selected patients. These include isometric exer-
cises such as physical counterpressure measures 
and acutely ingesting a glass of cold water. This 
therapeutic strategy is shown in Figure 5.
A pharmacologic strategy utilizing this approach 
might involve a “pill-in-the-pocket” approach, 
a fast-acting medication that would exert a thera-
peutic effect quickly and could be delivered rapidly. 
At this time, no such therapy exists. However, 
Raviele et al. [44] demonstrated in their small 
randomized study of 10 patients that patients 
could recognize initial symptoms of vasovagal 
syncope during head-up tilt testing and deliver 
a dose of phenylephrine in this premonitory phase. 
Compared to placebo, patient-triggered injection of 
phenylephrine was significantly more effective in 
decreasing symptoms and hypotension during the 
test. A non-pharmacologic strategy utilizing a simi-
lar approach is currently being pursued. Selective 
electronic stimulation of the autonomic nervous 
system is, in concept, an excellent way to provide 
targeted therapy for patients with autonomic dys-
function. Sympathetic stimulation via the renal 
veins is currently being studied in animal models 
[45]. It is foreseeable that an implantable renal vein 
stimulator coupled with an invasive hemodynamic 
monitor could be developed that would provide 
therapy only as the blood pressure approached 
a programmed threshold that had been associated 
with symptoms of cerebral hypoperfusion in the 
particular patient. Similarly, patients with cardio-
vagal dysfunction and intermittent tachycardia may 
benefit from intermittent vagus nerve stimulation.
Finally, the most appealing model of disease 
treatment would be to identify the factors respon-
sible for the autonomic dysregulation and treat 
these upstream of the effects (Fig. 6). Further 
research is needed to articulate these underlying 
upstream mechanisms. For instance, autoantibody-
-mediated autonomic dysfunction could be treated 
by immunomodulatory medications. It is not unrea-
sonable to speculate that pharmacologic therapy 
in the form of a neurotransmitter modulator, 
a neuroprotective agent, or a neuroregenerative 
agent could potentially restore normal physiology. 
Nonpharmacologic treatments in the form of 
central nervous system stimulation or stem cell 
therapies could potentially act in this upstream 
fashion. This approach depends on further research 
Figure 4. A model of chronic maintenance therapy to 
treat paroxysmal symptoms; HR — heart rate; MAP — 
mean arterial pressure.
Figure 5. A model of acute intermittent therapy to 
treat paroxysmal symptoms; HR — heart rate; MAP — 
mean arterial pressure.
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into the underlying mechanisms behind IAST and 
POTS. Given the heterogeneity and overlap in 
each disorder, there are likely multiple and distinct 
upstream mechanisms at work.
Conclusions
Patients with episodic ST and associated OI pre-
sent a diagnostic and management dilemma to the 
clinician. Secondary ST should first be ruled out. The 
subsequent differential diagnosis includes SNRT, 
IAST, and POTS. Management of SNRT is straight 
forward with catheter ablation if the patients can-
not tolerate their symptoms. Patients with POTS 
or IAST often have disabling symptoms despite 
extensive medical investigations and multiple 
empiric therapies. Both patients and clinicians are 
frustrated by the lack of clear diagnostic algo rithms, 
treatment targets, and efficacious therapies.
We favor a multidisciplinary approach involv-
ing at minimum primary care, cardiology, and neu-
rology, with input from mental health and physical 
therapy providers when needed. Our approach to 
treatment focuses on defining abnormal cardiac 
and autonomic parameters during the diagnostic 
workup and then attempting to target treatment to 
the putative mechanism. Side effects of the current 
available pharmacologic and nonpharmacologic 
therapies are frequent. Conservative therapy by 
making lifestyle adjustments and a trial of medi-
cations is recommended as the initial approach. 
Midodrine and fludrocortisone are available to treat 
hypovolemia, venous pooling, and adrenergic dys-
function; but monitoring is recommended to avoid 
supine hypertension. Beta-adrenergic antagonists 
reduce the HR and may provide symptomatic 
benefit. Ivabradine has demonstrated efficacy in 
multiple small trials in IAST.
The knowledge gap regarding the mechanisms 
underlying these conditions is a major barrier in 
developing effective therapies. A better understanding 
of the plausible autonomic dysregulation mediating 
POTS or IAST and a paradigm shift in considering 
“pulse therapy” or “upstream therapy” in autonomic 
intervention warrants further investigation.
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